Pagel Unpacks the Utility of PI3K Inhibitors in Lymphoid Malignancies
Season 5, Episode 1, Apr 22, 2021, 05:56 PM
Dr. Pagel discusses the advances that have been made with PI3K inhibitors in lymphoid malignancies, the impact of the FDA approval of umbralisib on the treatment paradigm in follicular lymphoma and marginal zone lymphoma, and ongoing research poised to expand the armamentarium.